Clinical Report: Troponin Testing and Early MI Discharge
Overview
Revise to explicitly state the negative predictive value and sensitivity for the primary outcome.
Background
The ability to accurately and rapidly diagnose myocardial infarction (MI) is crucial in emergency medicine, as it influences treatment decisions and patient outcomes. High-sensitivity cardiac troponin assays have revolutionized the assessment of myocardial injury, allowing for quicker rule-out of MI. However, the effectiveness of these assays in facilitating early discharge for low-risk patients remains an important area of investigation.
Data Highlights
Assay Type
Threshold
Patients Below Threshold
Negative Predictive Value
Sensitivity
Sixth-Generation
< 13 ng/L
61% (601/987)
99.9%
99.4%
Fifth-Generation
< 5 ng/L
28% (271)
99.8%
99.4%
Key Findings
61% of patients had sixth-generation troponin T concentrations < 13 ng/L at presentation.
The sixth-generation assay had a negative predictive value of 99.9% for the primary outcome.
41% of patients would be classified as low risk using the sixth-generation assay compared to 17% with the fifth-generation assay.
Application of the sixth-generation assay reduced the need for serial troponin testing (23% vs 43%).
In external validation, 45% of patients had sixth-generation troponin T concentrations < 13 ng/L.
Clinical Implications
The findings suggest that the sixth-generation high-sensitivity cardiac troponin T assay may facilitate earlier discharge for low-risk patients with suspected MI, potentially reducing unnecessary hospital stays and serial testing. Clinicians should consider the assay's performance characteristics when making discharge decisions.
Conclusion
The sixth-generation high-sensitivity cardiac troponin T assay shows promise in improving early discharge rates for low-risk patients with suspected myocardial infarction, warranting further prospective studies to confirm its clinical utility.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.
